Posted by Michael Wonder on 03 Nov 2020
FDA approves updated label for Endari
3 November 2020 - Emmaus Life Sciences announced today revised prescribing information for Endari to better inform healthcare professionals and sickle cell disease patients.
Based on approval from the FDA, the updated label includes a statement that the clinical benefit of Endari was observed irrespective of hydroxyurea usage and a new step-by-step instruction for use section at the end of the prescribing information.
